Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey.

Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey.

GPR40 (FFAR1) is a promising target for the managing type 2 diabetes (T2D). The most advanced GPR40 agonist TAK-875 exhibited satisfactory glucose-lowering effects in phase II and III studies. However, the phase III studies of TAK-875 revealed drug-induced liver injury (DILI). It is unknown whether...

Full description

Bibliographic Details
Main Authors: Katarzyna Bazydlo-Guzenda, Pawel Buda, Mateusz Mach, Jerzy Pieczykolan, Izabela Kozlowska, Michal Janiszewski, Ewa Drzazga, Jakub Dominowski, Hubert Ziolkowski, Maciej Wieczorek, Shayne Cox Gad
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0257477

Internet

https://doi.org/10.1371/journal.pone.0257477

Similar Items